Inflammatory myopathies

Infections as a predominant cause of death in adult patients with idiopathic inflammatory myopathies

Clin Exp RheumatolPublished Retrospective cohort study

Authors' conclusion

Patients with IIM associated with cardiac involvement and concomitant autoimmune diseases may be at higher risk of fatal outcomes. Infections were the predominant cause of death in our cohort of patients. The majority of fatal outcomes occurred at the relatively early stage of the disease.

Study context

Population
Adults with idiopathic inflammatory myopathies (IIM) (mostly ASyS, DM and PM), single-centre Polish cohort
Participants
79 adults
Exposure
Deceased vs survived IIM patients
  • Deceasedn = 9
Outcome
Causes of death and risk factors for fatal outcomes
Methodological detailssingle-centre
  • Single-centre

Main finding

As reported in the abstract

Mortality and causes of death

Deceased

11.39%

9

Deceased vs Survived: P = 0.026 · Deceased vs Survived: P = 0.028 · Deceased vs Survived: P = 0.005 · Deceased vs Survived: P = 0.006

Deaths caused by infections, predominantly respiratory tract
89.89%
Deaths within first 18 months after IIM diagnosis
77.78%
Deaths caused by malignancy
0

Observational data: associations, not effects.

Further findings

OutcomeP value
Factors more frequent in deceased vs survivorsDeceased vs SurvivedP = 0.026
Factors more frequent in deceased vs survivorsDeceased vs SurvivedP = 0.028
Factors more frequent in deceased vs survivorsDeceased vs SurvivedP = 0.005
Factors more frequent in deceased vs survivorsDeceased vs SurvivedP = 0.006

Cohort characteristics

Median diagnostic delay (months)
5
Deaths within the first 18 months after IIM diagnosis
77.78%
History of malignancy
10.13%
Deaths caused by malignancy
0

Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.

Original publication

Infections as a predominant cause of death in adult patients with idiopathic inflammatory myopathies. Clin Exp Rheumatol. Published 26 February 2025. doi:10.55563/clinexprheumatol/kcdmct

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.